A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in human epidermal growth factor receptor 2 negative, hormone receptor-positive breast cancer patients with bone metastases

被引：0

作者：

Rugo, H. S.

Huang, L.

Petrenciuc, O.

Zaccarini, P.

Coleman, R. E.

机构：

[1] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[2] Bayer HealthCare, Whippany, NJ USA

[3] Bayer SpA, Milan, Italy

[4] Univ Sheffield, Weston Pk Hosp, Sheffield, S Yorkshire, England

来源：

CANCER RESEARCH | 2016年 / 76卷

关键词：

D O I：

10.1158/1538-7445.SABCS15-OT2-01-11

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OT2-01-11

引用

页数：2

共 50 条

[41] BOLERO-2: Everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone receptor-positive breast cancer.
Noguchi, Shinzaburo
Masuda, Norikazu
Ito, Yoshinori
Iwata, Hiroji
Mukai, Hirofumi
Horiguchi, Jun
Tokuda, Yutaka
Kuroi, Katsumasa
Iwase, Hirotaka
Inaji, Hideo
Ohsumi, Shozo
Piccart-Gebhart, Martine J.
Hortobagyi, Gabriel N.
Rugo, Hope S.
Gnant, Michael
Campone, Mario
Sahmoud, Tarek
Pritchard, Kathleen I.
Burris, Howard A.
Baselga, Jose
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[42] Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Baselga, Jose
Im, Seock-Ah
Iwata, Hiroji
Cortes, Javier
De laurentiis, Michele
Jiang, Zefei
Arteaga, Carlos L.
Jonat, Walter
Clemons, Mark
Ito, Yoshinori
Awada, Ahmad
Chia, Stephen
Jagiello-Gruszfeld, Agnieszka
Pistilli, Barbara
Tseng, Ling-Ming
Hurvitz, Sara
Masuda, Norikazu
Takahashi, Masato
Vuylsteke, Peter
Hachemi, Soulef
Dharan, Bharani
Di Tomaso, Emmanuelle
Urban, Patrick
Massacesi, Cristian
Campone, Mario
LANCET ONCOLOGY, 2017, 18 (07): : 904 - 916
[43] Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: A multicenter, randomized, double- blind, placebo-controlled, phase 3 trial
Xu, Binghe
Zhang, Qingyuan
Hu, Xichun
Li, Qing
Sun, Tao
Li, Wei
Ouyang, Quchang
Wang, Jingfen
Tong, Zhongsheng
Yan, Min
Li, Huiping
Zeng, Xiaohua
Shan, Changping
Wang, Xian
Yan, Xi
Zhang, Jian
Zhang, Yue
Wang, Jiani
Zhang, Liang
Lin, Ying
Feng, Jifeng
Chen, Qianjun
Huang, Jian
Zhang, Lu
Yang, Lisong
Tian, Ying
Shang, Hongyan
ACTA PHARMACEUTICA SINICA B, 2023, 13 (05) : 2250 - 2258
[44] Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102
Kornblum, Noah
Zhao, Fengmin
Manola, Judith
Klein, Paula
Ramaswamy, Bhuvaneswari
Brufsky, Adam
Stella, Phillip J.
Burnette, Brian
Telli, Melinda
Makower, Della F.
Cheema, Puneet
Truica, Cristina I.
Wolff, Antonio C.
Soori, Gamini S.
Haley, Barbara
Wassenaar, Timothy R.
Goldstein, Lori J.
Miller, Kathy D.
Sparano, Joseph A.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (16) : 1556 - +
[45] Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors
Groheux, David
Hatt, Mathieu
Hindie, Elif
Giacchetti, Sylvie
de Cremoux, Patricia
Lehmann-Che, Jacqueline
Martineau, Antoine
Marty, Michel
Cuvier, Caroline
Cheze-Le Rest, Catherine
de Roquancourt, Anne
Visvikis, Dimitris
Espie, Marc
CANCER, 2013, 119 (11) : 1960 - 1968
[46] How to Treat Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Amplified Breast Cancer
Cortes, Javier
Baselga, Jose
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (33) : 5492 - 5494
[47] Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2
Piccart, M.
Hortobagyi, G. N.
Campone, M.
Pritchard, K. I.
Lebrun, F.
Ito, Y.
Noguchi, S.
Perez, A.
Rugo, H. S.
Deleu, I.
Burris, H. A., III
Provencher, L.
Neven, P.
Gnant, M.
Shtivelband, M.
Wu, C.
Fan, J.
Feng, W.
Taran, T.
Baselga, J.
ANNALS OF ONCOLOGY, 2014, 25 (12) : 2357 - 2362
[48] Combination of Palbociclib and Endocrine Therapy in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer With or Without Brain Metastases
Zhang, Qiuyi
Lan, Xiaofeng
Huang, Jiayi
Xie, Xiaofeng
Chen, Liping
Song, Lin
Bai, Xue
Chen, Xuelian
Jing, Haiman
Du, Caiwen
TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2024, 23
[49] Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer: a long-term safety and overall survival update from the randomised, double-blind, placebo-controlled, phase 3 trial
Zhang, Qingyuan
Li, Wei
Hu, Xichun
Sun, Tao
Cui, Shude
Wang, Shusen
Ouyang, Quchang
Yin, Yongmei
Geng, Cuizhi
Tong, Zhongsheng
Cheng, Ying
Ning, Zhiqiang
Jiang, Zefei
TRANSLATIONAL BREAST CANCER RESEARCH, 2023, 4
[50] Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: A double-blind placebo-controlled phase II randomised trial
Polychronis, A
Sinnett, HD
Hadjiminas, D
Singhal, H
Monsi, JL
Shivapatham, D
Shousha, S
Jiang, J
Peston, D
Barrett, N
Vigushin, D
Morrison, K
Beresford, E
Ali, S
Slade, MJ
Coombes, RC
LANCET ONCOLOGY, 2005, 6 (06): : 383 - 391

← 1 2 3 4 5 →